Last reviewed · How we verify
Xiidra
At a glance
| Generic name | Xiidra |
|---|---|
| Also known as | Lifitegrast, Lifitegrast Ophthalmic Solution |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Target | Integrin alpha-L/beta-2, Intercellular adhesion molecule 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Tear film insufficiency
Common side effects
- Instillation-site irritation
- Dysgeusia
- Decreased visual acuity
- Blurred vision
- Conjunctival hyperemia
- Eye irritation
- Headache
- Increased lacrimation
- Eye discharge
- Eye discomfort
- Eye pruritus
- Sinusitis
Serious adverse events
- Anaphylactic reaction
- Bronchospasm
- Respiratory distress
- Pharyngeal edema
- Angioedema
- Dyspnea
- Urticaria
- Allergic conjunctivitis
- Eye swelling
- Rash
Key clinical trials
- This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye (PHASE4)
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (PHASE2)
- Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
- A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease (PHASE3)
- Switching From Xiidra to TRYPTYR (PHASE4)
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (PHASE4)
- Lifitegrast Eye Drops in Healthy Subjects：Phase I Study (PHASE1)
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xiidra CI brief — competitive landscape report
- Xiidra updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI